TMSP(SH:600671)2019-08-27 16:00Financial Performance - Operating revenue for the first nine months was ¥290,220,477.05, representing a significant increase of 243.48% year-on-year[7]. - The net profit attributable to shareholders of the listed company for the first nine months was a loss of ¥10,758,154.09, an improvement from a loss of ¥12,450,596.07 in the previous year[7]. - Basic earnings per share for the reporting period was ¥0.0622, down by 11.27% compared to ¥0.0701 in the same period last year[7]. - The company reported a net loss of CNY 122,772,682.05, an improvement from a loss of CNY 130,346,366.64 in the previous period[23]. - The total comprehensive income for the period was CNY -840,234.07, compared to CNY 16,477,910.88 in the same period last year, indicating a decline in overall profitability[32]. Cash Flow - Net cash flow from operating activities for the first nine months was ¥22,668,349.45, a remarkable increase of 2,543.10% compared to the same period last year[7]. - The company’s cash flow from financing activities was ¥12,842,764.61, a turnaround from a cash outflow of ¥3,025,407.72 in the previous year, indicating improved financing conditions[16]. - The net cash flow from operating activities for the first nine months of 2018 was CNY 22,668,349.45, a significant increase compared to CNY 857,644.13 in the same period last year, reflecting a growth of over 2,500%[35]. - The total cash inflow from operating activities reached CNY 286,517,565.10, compared to CNY 96,354,195.50 in the previous year, indicating a year-over-year increase of approximately 197%[35]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥439,160,782.06, an increase of 1.80% compared to the end of the previous year[7]. - Non-current assets rose to CNY 306,635,187.77, up from CNY 224,336,776.10, indicating a significant increase of about 36.7%[22]. - Total liabilities decreased slightly to CNY 332,090,327.17 from CNY 334,177,059.45, a reduction of approximately 0.56%[23]. - Current liabilities totaled CNY 235,305,134.79, compared to CNY 230,497,485.43, showing an increase of about 2.5%[22]. Inventory and Receivables - The company’s inventory increased to ¥61,435,696.56 from ¥57,001,953.39, reflecting a strategic buildup in preparation for future sales[21]. - Accounts receivable decreased by 74.01% to ¥1,300,739.00 from ¥5,004,521.86 primarily due to payments for goods[13]. - Prepayments decreased by 82.80% to ¥1,614,539.41 from ¥9,388,722.30, mainly due to a reduction in prepayments for raw materials[13]. Expenses - Operating costs rose to ¥178,876,405.83, reflecting a 252.41% increase from ¥50,758,140.49, primarily due to higher sales volume[15]. - The company incurred a sales expense of ¥55,071,553.99, which is a 263.03% increase from ¥15,170,002.40, attributed to adjustments in product pricing and increased sales activities[15]. - The company’s management expenses amounted to ¥31,970,958.07, up 51.81% from ¥21,059,608.94, mainly due to the consolidation of new subsidiaries[15]. Strategic Developments - The company plans to conduct large-scale production validation for the "Amoxicillin Clavulanate Potassium Tablets" in the upcoming month, following successful development phases[19]. - The company has established a framework agreement to acquire 100% equity of Shenmi Xixia from its controlling shareholder, which is pending board and shareholder approval[18]. - The company has not disclosed any new product developments or market expansion strategies in this report[10].